Biocon Corporate Presentation

Quarterly Financial Highlights Biocon Q 1 FY22 Q 1 FY21 Revenue +6% 1,808Cr *1,712Cr Biosimilars +10% | Research Services +41% | Generics (22)% Core EBITDA* (1)% *531Cr *532Cr % margin 30% 31% EBITDA +1% *437Cr *432Cr % margin 24% 25% Forex Gain of 17Cr in Q1 FY22 vs *4Cr of Forex loss in Q1 FY21 Gross R&D spends at #136Cr in Q1 FY22 vs 142Cr in Q1FY21 R&D spends in P&L *120Cr for Q1 FY22 Profit Before Tax (33)% *166Cr *249Cr PBT ex Bicara of 224Cr in Q1 FY22 % margin 9% 15% Net Profit (44)% €84Cr *149Cr Net Profit ex Bicara of *142Cr in Q1 FY22 % margin 5% 9% *Core EBITDA defined as EBITDA before R&D, forex and licensing income 20 20

View entire presentation